Congress Materials – American Academy of Neurology (AAN 2026)
2026 American Academy of Neurology | April 18-22 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Assessing the Relationship Between Immunoglobulin G Level and Efficacy of Nipocalimab Measured Using Myasthenia Gravis-Activities of Daily Living Scale
Zabeen Mahuwala, Ruben Faelens, Belen Valenzuela, Martine Neyens, Yaowei Zhu, Jocelyn H. Leu, Marie Fitzgibbon, Sindhu Ramchandren, Juan-Jose Perez Ruixo
This document wll be available after April 20 2026
Differences in Mortality Among Medicare Beneficiaries With and Without Generalized Myasthenia Gravis
Louis Jackson, Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak, Grace Chen, Daisy Liu, Dominic Pilon, Raghav Govindarajan
This document will be available after April 20 2026
Factors Associated with Recurrent Clinical Events among Pediatric Generalized Myasthenia Gravis Patients in the United States
Zhiwen Liu, Jacqueline Pesa, Louis Jackson, Liang-Yuan Lin, Alicia K. Campbell, Raghav Govindarajan
This document will be available after April 20 2026
Healthcare Costs in Commercially Insured Pediatric Patients with Generalized Myasthenia Gravis in the United States
Zhiwen Liu, Jacqueline Pesa, Louis Jackson, Liang-Yuan Lin, Alicia K. Campbell, Raghav Govindarajan
This document will be available after April 20 2026
Long-term Safety and Efficacy of Nipocalimab: Approximately Two Years Follow-up Results From the Open-label Extension Phase of Vivacity-MG3 Study
Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J. Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Panna Sanga, Ibrahim Turkoz, Yaowei Zhu, Marie Fitzgibbon, Michel Burcklen
This document will be available after April 20 2026
Quality of Life in Patients With Generalized Myasthenia Gravis Achieving Sustained Versus Transient Minimal Symptom Expression in the Phase Three Vivacity-MG3 Trial
Elena Cortés Vicente, Nolan Campbell, Kavita Gandhi, Marie Fitzgibbon, Ibrahim Turkoz
This document will be available after April 20 2026
Self-reported Clinical Characteristics of a U.S. Generalized Myasthenia Gravis Population Treated With Standard of Care Therapy: Results From a Real-world Patient Survey
Jacqueline Pesa, Louis Jackson, Gregor Gibson, Hannah Connolly, Shiva Lauretta Birija, Beth Poirrette, Amy Foster, Raghav Govindarajan
This document will be available after April 20 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.